PT  - JOURNAL ARTICLE
AU  - Doevelaar, Adrian A. N.
AU  - Bachmann, Martin
AU  - Hölzer, Bodo
AU  - Seibert, Felix S.
AU  - Rohn, Benjamin J.
AU  - Witzke, Oliver
AU  - Dittmer, Ulf
AU  - Brenner, Thorsten
AU  - Paniskaki, Krystallenia
AU  - Yilmaz, Serap
AU  - Dittmer, Rita
AU  - Schneppenheim, Sonja
AU  - Babel, Nina
AU  - Budde, Ulrich
AU  - Westhoff, Timm H.
TI  - Generation of Inhibitory Autoantibodies to ADAMTS13 in Coronavirus Disease 2019
AID  - 10.1101/2021.03.18.21253869
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.18.21253869
4099  - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253869.short
4100  - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253869.full
AB  - Objectives It has recently been shown that von Willebrand factor (vWf) multimers may be a key driver of immunothrombosis in Coronavirus disease 2019 (COVID-19). Since COVID-19 is associated with an increased risk of autoreactivity, the present study investigates, whether the generation of autoantibodies to ADAMTS13 contributes to this finding.Design Observational prospective controlled multicenter study.Setting Blood samples and clinical data of patients with COVID-19 were collected regularly during hospitalization in the period from April to November 2020.Patients 90 patients with confirmed COVID-19 of mild to critical severity and 30 healthy controls participated in this study.Measuerements and Main Results Antibodies to ADAMTS13 occurred in 31 (34.4%) patients with COVID-19. Generation of ADAMTS13 antibodies was associated with a significantly lower ADAMTS13 activity (56.5%, interquartile range (IQR) 21.25 vs. 71.5%, IQR 24.25, p=0.0041), increased disease severity (severe or critical disease in 90% vs. 62.3%, p=0.0189), and a trend to a higher mortality (35.5% vs. 18.6%, p=0.0773). Median time to antibody development was 11 days after first positive SARS-CoV-2-PCR specimen.Conclusion The present study demonstrates for the first time, that generation of antibodies to ADAMTS13 is a frequent finding in COVID-19. Generation of these antibodies is associated with a lower ADAMTS13 activity and an increased risk of an adverse course of the disease suggesting an inhibitory effect on the protease. These findings provide a rationale to include ADAMTS13 antibodies in the diagnostic workup of SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been granted.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the research has been given by ethical comitees of Ruhr-University Bochum (20-6886) University Hospital Essen (20-9214-BO) and the Medical Association HamburgAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo referral to additional Data or supplementary material.